Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases

Phase 1

Completed

• Conditions: Bone Neoplasms

• Registration Number: NCT00168129
• Lead Sponsor: Alberta Health services

Brief Summary

To assess the safety and efficacy of a single fraction of radiotherapy using helical tomotherapy to treat bone metastases.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-06
• Study Completion: 2005-07
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-15
• Status Verified: 2011-12
• Last Update Submitted: 2011-12-08
• Last Update Posted: 2011-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• painful metastatic bone disease from any malignancy

Exclusion Criteria

• previous RT to same area
• contraindications to RT

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
To deliver a single fraction of radiotherapy safely to patients with bone metastases using helical tomotherapy

Secondary Outcome Measures

Name	Time	Method
To assess and quantify the acute toxicity of patients with bone metastases treated with helical tomotherapy.
To measure invivo dosimetry and compare delivered doses to computer-reconstructed dose distribution.
To determine the maximum tolerated does of palliative radiation give with helical tomotherapy in a single fraction.
To assess the efficacy (pain control) of radiotherapy given with helical tomotherapy.

Trial Locations

Locations (1)

Cross Cancer Institute; 🇨🇦 Edmonton, Alberta, Canada